These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1963117)

  • 21. Epidemiology of poliomyelitis--options and update.
    Dutta A
    Vaccine; 2008 Oct; 26(45):5767-73. PubMed ID: 18755232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The maintaining of the active laboratory-based surveillance of the acute flaccid paralysis (AFP) cases in Romania in the framework of the strategic plan of the global polio eradication initiative.
    Băicuş A; Persu A; Combiescu M; Aubert-Combiescu A
    Roum Arch Microbiol Immunol; 2007; 66(1-2):44-50. PubMed ID: 18928063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of candidates for new type 2 and type 3 oral poliovirus vaccines.
    Kohara M; Abe S; Yoshioka I; Nomoto A
    Dev Biol Stand; 1993; 78():141-8. PubMed ID: 8388824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poliomyelitis vaccination--choosing a wise policy.
    Salk J
    Pediatr Infect Dis J; 1987 Oct; 6(10):889-93. PubMed ID: 3696820
    [No Abstract]   [Full Text] [Related]  

  • 25. Update on vaccine-derived polioviruses--worldwide, January 2008-June 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Sep; 58(36):1002-6. PubMed ID: 19763076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antipolio prophylaxis of immunocompromised children during a nationwide oral poliovaccine campaign.
    Stenvik M; Hovi L; Siimes MA; Roivainen M; Hovi T
    Pediatr Infect Dis J; 1987 Dec; 6(12):1106-10. PubMed ID: 2829105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is there a need for a change in poliomyelitis immunization policy?
    Sabin AB
    Pediatr Infect Dis J; 1987 Oct; 6(10):887-9. PubMed ID: 3696819
    [No Abstract]   [Full Text] [Related]  

  • 28. Preliminary report: paralytic poliomyelitis--Senegal, 1986.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1987 Jun; 36(24):387-90. PubMed ID: 3108650
    [No Abstract]   [Full Text] [Related]  

  • 29. Immunity status to polioviruses among non-European union immigrants in Veneto Region (North-East Italy).
    Trivello R; Ngatchu T; Marin V; Moretti G; Malatesta R; Maini P; Moschen ME; Baldo V; De Marzi L; Majori S; Puppo A; Renzulli G
    Ann Clin Lab Sci; 1996; 26(2):154-9. PubMed ID: 8852425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polio control after certification: major issues outstanding.
    Fine PE; Oblapenko G; Sutter RW
    Bull World Health Organ; 2004 Jan; 82(1):47-52. PubMed ID: 15106300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Genetic changes in strains of poliovirus type 2 isolated from patients with vaccine-associated paralytic poliomyelitis].
    Sosa-Díaz RY; Más-Lago P; Valdés-Ramírez O; Sarmiento-Pérez L
    Rev Neurol; 2003 May 1-15; 36(9):812-6. PubMed ID: 12717666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on vaccine-derived polioviruses.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2006 Oct; 55(40):1093-7. PubMed ID: 17035927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of routine polio immunization in the post-certification era.
    Sutter RW; Cáceres VM; Mas Lago P
    Bull World Health Organ; 2004 Jan; 82(1):31-9. PubMed ID: 15106298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
    Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
    J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Oral poliomyelitis vaccination: why should transmission of vaccine viruses to unvaccinated infants be avoided if possible?].
    Wiersbitzky S
    Kinderarztl Prax; 1993 May; 61(3):120-1. PubMed ID: 8392122
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical trial of concentrated inactivated polio vaccine in a simplified immunization program.
    Fillastre C; Emmou C; Meyran M; Schlumberger M; Guérin N
    Dev Biol Stand; 1981; 47():207-13. PubMed ID: 6262148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [End phase challenges of poliomyelitis eradication programme realization].
    Jarzabek Z
    Przegl Epidemiol; 2005; 59(1):59-68. PubMed ID: 16013411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ethical and safety considerations for the use in clinical trials of new attenuated poliovirus strains.
    Horaud F
    Dev Biol Stand; 1993; 78():149-54; discussion 154-5. PubMed ID: 8388825
    [No Abstract]   [Full Text] [Related]  

  • 39. Molecular evolution of oral poliovirus vaccine strains during multiplication in humans and possible implications for global eradication of poliovirus.
    Friedrich F
    Acta Virol; 2000 Apr; 44(2):109-17. PubMed ID: 10989702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interrupting wild poliovirus transmission using oral poliovirus vaccine: environmental surveillance in high-risks area of India.
    Chowdhary R; Dhole TN
    J Med Virol; 2008 Aug; 80(8):1477-88. PubMed ID: 18551602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.